Inhibition of DHCR24 activates LXRα to ameliorate hepatic steatosis and inflammation

Inhibition of DHCR24 activates LXRα to ameliorate hepatic steatosis and inflammation

Abstract Liver X receptor (LXR) agonism has theoretical potential for treating NAFLD/NASH, but synthetic agonists induce hyperlipidemia in preclinical models. Desmosterol, which is converted by Δ24‐dehydrocholesterol reductase (DHCR24) into cholesterol, is a potent endogenous LXR agonist with anti‐i...

Full description

Bibliographic Details
Main Authors: Enchen Zhou, Xiaoke Ge, Hiroyuki Nakashima, Rumei Li, Hendrik J P van derZande, Cong Liu, Zhuang Li, Christoph Müller, Franz Bracher, Yassene Mohammed, Jan Freark deBoer, Folkert Kuipers, Bruno Guigas, Christopher K Glass, Patrick C N Rensen, Martin Giera, Yanan Wang
Format: Article
Language:English
Published: Springer Nature 2023-08-01
Series:EMBO Molecular Medicine
Subjects:
desmosterol
Kupffer cell
liver X receptor
nonalcoholic steatohepatitis
Δ24‐dehydrocholesterol reductase
Online Access:https://doi.org/10.15252/emmm.202216845

Internet

https://doi.org/10.15252/emmm.202216845

Similar Items